Study Shows that the Metastasis-Free Period Affects Prostate Cancer Patient Survival

A study from Michael T. Schweizer, MD, and colleagues at Johns Hopkins University in Baltimore Md. concluded that the longer the metastasis-free survival after a radical prostatectomy the longer overall survival in men who experience biochemical recurrence (PSA only recurrence) of their prostate cancer. This conclusion was made from a retrospectively study of 450 men [...]

Using Denosumab (Xgeva) To Combat Skeletal Complications in Prostate Cancer

Xgeva is a monoclonal antibody that inactivates RANKL, a protein that enhances osteoclast activity and survival. By inhibiting RANKL, Xgeva prevents skeletal-related events in men with bone metastasis from prostate cancer. Under no circumstances should a man who also has multiple myeloma use Xgeva. There have been studies that compared Xgeva to zolendronic acid (Zometa). [...]

On The Horizon- MRI Guided Ultrasound Ablation of Prostate Cancer Tumors

In 1999 there was a new company started, InSightec, when GE Healthcare and Elbit Medical imaging joined their technologies to develop and manufacture non-invasive magnetic resonance (MRI) guided focused ultrasound technologies. The company has been in the process of developing a system that combines MRIs with ultrasound to non-surgically destroy fibroids and tumors. The company [...]

Two New Sites Available for Early Access to Alpharadin

There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical site is NOT currently accurate. Additionally, there are [...]

Now an Early Access Site for Alpharedin Opens in New York

The Early Access Committee on which Malecare sits has been successful in adding an additional site in Long Island, New York to the Early Access Trial of Radium-233 Chloride (Alpharedin) for men with advanced prostate cancer who are castrate resistant and have at least two (2) bone metastases. If you are interested in this trial [...]

The FDA Approves a New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases

The big news from yesterday is that the Food and Drug Administration (FDA) has approved a MRI-guided, focused ultrasound therapy for the treatment of bone pain associated with metastatic advanced prostate cancer. In a media release written by InSight, an Israeli company states that its ExAblate® MRI-guided, focused ultrasound technology is indicated to treat pain [...]

Understanding Oligometastic Prostate Cancer & Our Ability to Successfully Treat It

It is the general consensus that prostate cancer when still confined to the prostate gland is gland curable, but when it has left the prostate gland and becoming metastatic it is no longer curable. But evidence now says there might be an intermediate stage where the cancer has spread outside the prostate gland but is [...]

Curcumin Might Curb the Development of Metastases in Advanced Prostate Cancer

Powdered turmeric is a common ingredient of Indian food and a substance that has been used for centuries to treat osteoarthritis and other illnesses. In March 2012 researchers from Michigan State University found that curcumin may be beneficial for people with Parkinson's disease as well as head and neck cancers. It is now thought that [...]

More Information About C11 Choline Scans & Some of the Other Alternative Scans Used to ID Focal Advanced Prostate Cancer Recurrences

Off-line I have received a number of additional questions about the use of imaging with c11 choline (see my post at The questions ranged from what is c11 choline to how it compares to some of the other more sensitive PET scans contrasts that are being used to identify specific locations of recurrent advanced [...]

A Possible Provenge Private Insurance Hitch In Men with Advanced Prostate Cancer

At a recent meeting that I attended it was reported by a nurse that one of her patients with advanced prostate cancer with only a PSA recurrence and lymph node involvement on a scan was rejected by their insurance company for reimbursement for Provenge. The insurance company indicated that to pay for the treatment they [...]